

# BMJ Open Prevalence, clinical features and risk assessment of pre-diabetes in Spain: the prospective Mollerussa cohort study

María Belén Vilanova,<sup>1</sup> Mireia Falguera,<sup>1</sup> Josep Ramon Marsal,<sup>2,3,4,5</sup> Esther Rubinat,<sup>6,7,8</sup> Núria Alcubierre,<sup>9</sup> Esmeralda Catelblanco,<sup>6,7,10</sup> Minerva Granado-Casas,<sup>6</sup> Neus Miró,<sup>11</sup> Àngels Molló,<sup>12</sup> Manel Mata-Cases,<sup>6,7,13</sup> Josep Franch-Nadal,<sup>6,7,14</sup> Didac Mauricio<sup>6,7,10</sup>

**To cite:** Vilanova MB, Falguera M, Marsal JR, *et al.* Prevalence, clinical features and risk assessment of pre-diabetes in Spain: the prospective Mollerussa cohort study. *BMJ Open* 2017;**7**:e015158. doi:10.1136/bmjopen-2016-015158

► Prepublication history for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2016-015158>).

Received 11 November 2016  
Revised 8 April 2017  
Accepted 2 May 2017

## ABSTRACT

**Purpose** The Mollerussa prospective cohort was created to study pre-diabetes in a population-based sample from the primary care setting in the semirural area of Pla d'Urgell in Catalonia (Spain). The aims of the study were to assess the prevalence of pre-diabetes in our population, the likelihood to develop overt diabetes over time and to identify risk factors associated with the progression of the condition.

**Participants** The cohort includes 594 subjects randomly selected between March 2011 and July 2014 from our primary care population, who were older than 25 years, consented to participate and did not have a recorded diagnosis of diabetes.

**Findings to date** At baseline, we performed a clinical interview to collect demographic, clinical and lifestyle (including a nutritional survey) characteristics; carotid ultrasound imaging to assess subclinical cardiovascular disease was also performed, and a blood sample was collected, with an overall <5% rate of missing data. An additional blood draw was performed 12 months after initial recruitment to reassess laboratory results in patients initially identified as having pre-diabetes, with an 89.6% retention rate. Several studies investigating various hypotheses are currently ongoing.

**Future plans** All subjects recruited during the cohort creation will be followed long-term through annual extraction of data from health records stored in the electronic Clinical station in Primary Care database. The Mollerussa cohort will thus be a sound population-based sample for multiple future research projects to generate insights into the epidemiology and natural history of pre-diabetes in Spain.

## INTRODUCTION

According to the American Diabetes Association (ADA), diabetes is broadly classified into four categories: type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), gestational diabetes and specific types of diabetes due to other causes.<sup>1</sup> However, there is a group of individuals that, in spite of having higher than normal glucose levels,

## Strengths and limitations of this study

- The Mollerussa cohort contains data from subjects with pre-diabetes identified in a primary care setting that were collected prospectively during 12 months, minimising recall bias.
- There was a potential selection bias, with higher rates for women and middle-aged among enlisted subjects than among eligible but not enlisted subjects, which will be minimised through a weighting process during the analyses.
- Subjects will be followed long-term through annual extraction of data included in the individuals' electronic medical records, a design that will minimise losses to follow-up.
- The long-term follow-up will allow the accurate estimation of time trends and clinical features associated with progression from pre-diabetes to overt diabetes
- A potential limitation of the long-term follow-up is that it will rely on data that may be incomplete or inconsistently measured between subjects

do not meet criteria for diabetes, a condition referred to as pre-diabetes.

There are different definitions of pre-diabetes, but the most common one, the ADA criteria, considers one of the following instances<sup>1</sup>: (a) impaired fasting plasma glucose (IFG), defined as fasting plasma glucose (FPG) between 100 and 125 mg/dL (5.6–5.9 mmol/L); or (b) impaired glucose tolerance (IGT), defined as a 2-hour plasma glucose value after a 75g oral glucose tolerance test (OGTT) between 140 and 199 mg/dL (7.8–11.0 mmol/L); or (c) glycated haemoglobin (HbA1c) levels between 5.7% and 6.4% (39–46 mmol/mol).

The prevalence of pre-diabetes varies across countries and depending on the parameter used for the estimations. Based solely on IGT, its worldwide prevalence among adults has been estimated by the International Diabetes



For numbered affiliations see end of article.

### Correspondence to

Dr Didac Mauricio;  
[didacmauricio@gmail.com](mailto:didacmauricio@gmail.com)

Federation to be 6.7% in 2015, with half of them (50.1%) younger than 50 years.<sup>2</sup> In England, solely based on HbA1c levels, the prevalence was 35.5% among the adult population in 2011<sup>3</sup>; in Spain, isolated IFG and isolated IGT were present in 3.4% and 2.9%, respectively, and combined IFG–IGT in 2.2% of the adult population in 2010<sup>4</sup>; and in the USA, using the ADA definition (HbA1c levels or IFG or IGT) the prevalence was as high as 38% in 2012.<sup>5</sup>

Understanding the epidemiology and natural history of pre-diabetes has become a health priority, in particular at the primary care setting, because it is a source of avoidable morbidity and mortality. First, individuals with IFG and/or IGT have a clinical phenotype that resembles patients with T2DM, as they tend to be older, have a higher body mass index (BMI), have more frequent insulin resistance and dyslipidaemia and have higher arterial blood pressure (BP) than people with normal glucose tolerance.<sup>6</sup> Second, people with pre-diabetes are at increased risk of developing diabetes: according to the ADA, up to 70% of them will eventually develop overt diabetes<sup>7</sup>; the annual incidence of progression to diabetes is around 5%–10% depending on the population characteristics and the definition of pre-diabetes; 6%–9% in subjects with isolated IFG, 4%–6% in those with isolated IGT, up to 15%–19% among those with both IFG and IGT<sup>8,9</sup> and subjects with HbA1c levels from 5.7% to <6.5% have a 7.5-year predicted risk of 43.1% for incident diabetes.<sup>10</sup> Finally, individuals with pre-diabetes are at increased risk of cardiovascular disease (CVD) and premature mortality: a meta-analysis found that the risk of CVD is increased regardless of type of blood glucose assessment in comparison to subjects with normoglycaemia<sup>11</sup>; and another recent meta-analysis found that risks of all-cause and CVD mortality compared with normoglycaemic subjects were increased in individuals with pre-diabetes with ADA defined IFG, IGT or both criteria combined, although not with isolated IFG.<sup>12</sup>

Based on epidemiological and clinical evidence, it is important from a prediction and prevention perspective to target segments of the population with metabolic and cardiovascular (CV) signatures associated with an increased risk of developing diabetes and CVD.<sup>1</sup> The Mollerussa cohort was designed to identify undiagnosed diabetes or pre-diabetes in the adult primary care population from a semirural area of Catalonia (Spain), and to further obtain extensive epidemiological, clinical (including subclinical atherosclerotic disease) and lifestyle data. In the following phases, the cohort will be run as prospective observational studies involving identified at-risk individuals to determine the progress over time regarding risk factors, incident diabetes, incidence of CV events, rates of hospitalisation and global mortality.

## COHORT DESCRIPTION

Mollerussa is a prospective observational cohort study conducted in Pla d'Urgell, a semirural area of Catalonia (Spain), among subjects from the general population

with healthcare coverage from the Catalan Institute of Health (Institut Català de la Salut).

Based on an estimated prevalence of pre-diabetes in the area of Lleida of 11% (10%–19%) in 2011,<sup>13</sup> we initially calculated that we would need a representative sample of 940 adults considering a 95% CI and a margin of error of  $\pm 2\%$ . However, literature published after the initiation of the recruitment phase, using HbA1c levels and ADA criteria, reported pre-diabetes prevalence between 35.5% and 38%.<sup>3,5</sup> Using this datum, a random sample of 505 subjects was sufficient to assess an estimated prevalence of about 30% with a 95% CI and a margin of error of  $\pm 4\%$ .

## Recruitment

Using the electronic Clinical station in Primary Care (eCAP) health records database implemented in all primary care centres in Catalonia, a code number was given to each registered adult. During the recruitment phase, 24666 registered health records met inclusion criteria, namely subjects older than 25 years and attending any Primary Healthcare Centre in the same health area in Pla d'Urgell (box 1; figure 1); among them, 2226 random individuals (about 5% of the total number of individuals registered at each centre) were contacted by telephone (up to three attempts) and invited to participate (figure 1). Randomisation was carried out using a randomiser programme (SPSS software V.16.0 for Windows; SPSS), following the principles of simple random sampling.

Main exclusion criteria (box 1) included a previous diagnosis of diabetes (T1DM, T2DM and any specific subtype of diabetes), and subjects on treatment with oral antidiabetic drugs to avoid the inclusion of individuals with actual diabetes but optimal glycaemic control, or even without diabetes but using metformin as treatment for other conditions. Based on their willingness to join the study and exclusion criteria, a total of 602 subjects were recruited and subsequently invited for an appointment, of whom four withdrew consent and, for four, we did not obtain any baseline laboratory data, therefore giving a final study population of 594 subjects.

## Data collection

The research plan included a first phase involving two visits to the primary healthcare centre for baseline screening, a second phase conducted 12 months after the baseline visits and a third phase of long-term follow-up of the cohort.

### First phase or baseline screening

The following variables were collected/explored by trained research staff in the first visit to the subject's primary healthcare centre: (a) Sociodemographic variables: age; gender; education level according to the International Standard Classification of Education<sup>14</sup>; sector of working activity (primary, secondary or manufacturing, tertiary or services); self-perceived work activity (minimum, light, moderate, heavy); report on

**Box 1 Summary of inclusion and exclusion criteria****Inclusion criteria**Age  $\geq 25$  years

Attended a primary health care centre in the area

**Exclusion criteria**

Patient information about having diabetes provided in the first contact or existing ICD-10 code of diabetes (E11, E14 or E13) registered by a physician or confirmed based on clinical data:

- ▶ HbA1c  $\geq 6.5\%$
- ▶ IGT: 2-hour plasma glucose in the 75g OGTT  $\geq 200$  mg/dL (11.1 mmol/L)
- ▶ IFG: FPG  $\geq 126$  mg/dL (7 mmol/L)

Specific subtypes of diabetes other than T1DM and T2DM:

- ▶ Gestational diabetes
- ▶ Genetic defect of beta-cell action
- ▶ Genetic defect in insulin action
- ▶ Diseases of the exocrine pancreas (eg, pancreatitis, haemochromatosis, pancreatic cancer, cystic fibrosis)
- ▶ Endocrinopathies (eg, Cushing's syndrome, glucagonoma, somatostatinoma, hyperthyroidism, pheochromocytoma, acromegaly)
- ▶ Chemical-induced diabetes
- ▶ Diabetes secondary to infections
- ▶ Autoimmune diabetes

Use of oral antidiabetic drugs: metformin, dipeptidyl peptidase-4 inhibitors, sulfonylureas and glitazones

Presence of cardiovascular disease:

- ▶ Previous hospitalisation to treat heart disease
- ▶ Heart failure
- ▶ Left bundle branch block or second degree atrioventricular block
- ▶ Aortic stenosis
- ▶ Systolic BP  $>180$  mm Hg or diastolic BP  $>105$  mm Hg

Cancer treated in the preceding 5 years, except non-melanoma skin cancers (basal-cell and squamous-cell carcinoma)

Kidney disease, defined as plasma creatinine  $\geq 1.4$  mg/dL in men and  $\geq 1.3$  mg/dL in women or proteinuria  $>2+$ Anaemia, defined as haematocrit  $<36\%$  in men and  $<33\%$  in women  
Hepatitis, defined as transaminases more than 10 times the upper the limit of normal

Gastrointestinal diseases (pancreatitis, irritable bowel disease and inflammatory bowel disease)

Recent abdominal surgery

Chronic pulmonary obstructive disease requiring domiciliary oxygen therapy

Chronic infectious diseases (eg, HIV, active tuberculosis, HBV and HCV)

Use of systemic glucocorticoids or beta blockers

Major psychiatric disorder with psychotic symptoms

BP, blood pressure; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; HBV, hepatitis B virus; HCV, hepatitis C virus; ICD, International Classification of Diseases; IFG, impaired fasting plasma glucose; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.

physical activity according to the Spanish-validated International Physical Activity Questionnaire<sup>15</sup>; family history of hypertension, dyslipidaemia, hypertriglyceridaemia, diabetes mellitus and acute myocardial infarction or angina pectoris; personal history of hypertension, dyslipidaemia, hypertriglyceridaemia, alcohol consumption and


smoking habit as reported by the patient; and current medication. (b) Anthropometric measures and physical examination: BP recorded according to the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines<sup>16</sup>; heart rate; body weight; waist circumference; and calculation of BMI. (c) Nutritional survey: food intake was assessed using a Spanish-validated version of the semiquantitative Food Frequency Questionnaire<sup>17</sup>; and we estimated the degree of adherence to the traditional Mediterranean diet through the Mediterranean Diet score.<sup>18</sup> (d) Carotid ultrasound imaging to measure intima-medial thickness and to assess the presence of carotid atherosclerotic plaques as previously described.<sup>19</sup> Briefly, both carotids were examined following a standardised operational procedure and the Mannheim consensus,<sup>20</sup> consisting of a cross-sectional view of the common, bulb and internal segments of the carotid arteries to identify atherosclerotic plaques (defined as a focal encroachment into the lumen of the carotid), and an online average measurement of the carotid intima-media thickness (c-IMT) of these three areas, with values of c-IMT above 1.5 mm considered as plaques.<sup>21</sup>

In a second appointment, the following laboratory measurements were obtained in fasting conditions: complete blood count, lipid, liver, kidney and thyroid profile. The study of glycaemia included the measurement of FPG and HbA1c. According to the ADA HbA1c criteria,<sup>1</sup> patients were classified into three groups: (1) without glucose metabolism disorders (HbA1c  $<5.7\%$ ), (2) with pre-diabetes (HbA1c between 5.7% and 6.4%) or with undiagnosed diabetes (HbA1c  $\geq 6.5\%$ ). When the investigator detected a case of undiagnosed diabetes, the individual was re-contacted and advised to visit a general practitioner at his/her corresponding primary health-care centre.

The baseline assessment will allow a first estimation of the prevalence of pre-diabetes in our population, its associated factors, and whether these subjects also have a higher prevalence of subclinical carotid atherosclerosis (and are therefore at high risk of CVD) compared with normoglycaemic subjects. Moreover, it will build on previous estimates of the prevalence of undiagnosed diabetes in primary healthcare in Catalonia.<sup>22</sup>

**Second phase or short-term follow-up**

Twelve months after the baseline visits, subjects initially fulfilling pre-diabetes criterion underwent a second visit to perform another blood draw to reassess the laboratory results. This was based on the ADA recommendation to repeat testing in the absence of unequivocal hyperglycaemia.<sup>1</sup> Based on re-evaluated HbA1c levels, those subjects with HbA1c levels between 5.7% and 6.4% were confirmed as pre-diabetes; those with a subsequent increase from pre-diabetes values at baseline to HbA1c  $\geq 6.5\%$  after 12 months were considered as incident diabetes (and as well re-contacted and advised to visit a general practitioner); and those with a further decrease



**Figure 1** Mollerussa study flow chart. CH, clinical history; HbA1c, glycated haemoglobin.

from pre-diabetes values at baseline to HbA1c <5.7% after 12 months as regression to normoglycaemia, although they will be followed up to rule out a temporary improvement, and thus a false case of regression to normal mean HbA1c values.

The 12-month follow-up will give a real estimation of pre-diabetes prevalence, valuable information on the 1-year probability of progression to diabetes and which risk factors were relevant to the further development of the disease (eg, metabolic traits and lifestyle).

### Third phase or long-term follow-up

In addition to the 12-month follow-up, we also plan to follow all subjects enrolled in the Mollerussa cohort annually through cross-sectional extraction of data stored in the primary care electronic medical records of the eCAP database.<sup>23</sup> This is based on the ADA recommendation to follow pre-diabetes in asymptomatic adults yearly.<sup>1</sup> We will extract data for the following variables: any diagnosis of T2DM (International Classification of Disease (ICD-10) codes E11 or E14)<sup>22</sup>; time since diagnosis; estimated glomerular filtration rate using the Modified Diet in Renal Disease formula; standardised HbA1c values, using the most recent value of the preceding 12 months; presence of CVD, including coronary artery disease (ICD-10 codes I20, I21, I22, I23 or I24), stroke (ICD-10 codes I63, I64, G45 or G46) and peripheral artery disease (ICD-10 code I73.9); risk factors, including BMI (most recent value in the last 12 months), cholesterol levels (total, low-density lipoproteins or LDL-cholesterol and high-density lipoproteins or HDL-cholesterol; most recent value in the last 12 months), BP (systolic and diastolic mean value in the last 12 months); and data on prescribed glucose-lowering, lipid-lowering, antihypertensive and antithrombotic medications. This information will be supplemented with data registered in the Conjunto Mínimo Básico de Datos de Altas Hospitalarias (Set of Minimum Basic Data Set of Hospital Admissions),<sup>24</sup> which records all admissions to public and private hospitals in the region and contains information on diagnostics, procedures and discharge reports.

With this additional longitudinal approach, we will be able to obtain the patient's data on progression to overt diabetes and/or initiation of antidiabetic treatment over time (if directly related to diabetes). This is important because besides the annualised incidence rate of progression to diabetes, the time course progression of dysglycaemia has not been studied at large. From the few available studies, the mode of onset of diabetes in subjects with pre-diabetes follows a non-linear pattern, with a rapid rather than gradual onset of diabetes over a 3-year time.<sup>25</sup> Moreover, we will be able to obtain data on the incidence of other diabetes-associated chronic conditions also present at the pre-diabetes stages, such as nephropathy, neuropathy or retinopathy; the incidence of macrovascular complications over time; the likelihood of initiation of hypoglycaemic agents among progressors; rates and cause of hospitalisations; and overall mortality.

This study was approved by the Ethics Committee of the Primary Healthcare University Research Institute (Institut d'Investigació en Atenció Primària, IDIAP) Jordi Gol (P12/043), and all patients signed a written informed consent form prior to participation. The study was conducted in accordance with the Declaration of Helsinki (1964).

### FINDINGS TO DATE

The Mollerussa study completed its recruitment phase between August 2011 and July 2014, and the 12-month short-term follow-up in July 2015. The enlisted sample (n=602) was different from the eligible but not enlisted population (n=784) in terms of gender and age (table 1); the enlisted sample had a significantly higher proportion of women (58.6% vs 44.0%; p<0.001), and was older (mean age 48.1 years vs 45.7 years; p<0.001).

Demographic characteristics of participants who provided a blood sample during the first phase (baseline visit) are summarised in table 2.

After the first phase, the rate of missing data was less than 5% across variables of interest (table 3), which is far below the 20% maximum recommended lost to follow-up

**Table 1** Age and gender characteristics between subjects eligible but not enlisted and subjects eventually enlisted in the Mollerussa cohort

	Eligible but not enlisted			Enlisted (n=602)
	Failed to be contacted (n=448)	Declined to participate (n=349)	All (n=797)	
<b>Gender (female), n (%)</b>	181 (40.4)	170 (48.7)	351 (44.0)	353 (58.6)*
<b>Age, years, mean (SD)</b>	44 (15.0)	47.9 (16.3)	45.7 (15.7)	48.1 (13.4)†
<b>Age group, years, n (%)</b>				
<40	218 (48.7)	140 (40.1)	358 (44.9)	168 (28.2)
40–60	160 (35.7)	125 (35.8)	285 (35.8)	315 (52.9)
>60	70 (15.6)	84 (24.1)	154 (19.3)	113 (19.0)

\* $\chi^2$  test, p<0.001.

†Kruskal-Wallis non-parametric test, p<0.001.

**Table 2** Demographic characteristics of study population enrolled in the Mollerussa cohort

Characteristic	Total valid N	Statistic
<b>Gender, women, n (%)</b>	594	347 (58.4)
<b>Age, years, mean (SD)</b>	594	50.6 (13.3)
<b>Weight, kg, mean (SD)</b>	574	73.1 (14.5)
<b>Waist, cm, mean (SD)</b>	573	94.2 (12.5)
<b>Body mass index, kg/m<sup>2</sup>, mean (SD)</b>	573	26.3 (4.7)
<25.0, n (%)		236 (41.2)
25.0–29.9, n (%)		235 (41.0)
≥30.0, n (%)		102 (17.8)
<b>Education level, n (%)</b>	575	
Not even primary school		24 (4.2)
Completed primary school		122 (21.2)
Secondary/high school		366 (63.7)
Graduate or higher		63 (11)
<b>Work activity, n (%)</b>	572	
Employed		393 (68.7)
Unemployed		65 (11.4)
Disability		12 (2.1)
Retired		102 (17.8)
<b>Hypertension, n (%)</b>	571	102 (17.9)
<b>Dyslipidaemia, n (%)</b>	571	131 (22.9)
<b>Hypertriglyceridaemia, n (%)</b>	554	22 (4.0)
<b>Smokers, n (%)</b>	594	
Current		152 (25.6)
Former		148 (24.9)
<b>Alcohol consumption, n (%)</b>	573	286 (49.9)

rate in a cohort study.<sup>26</sup> Twelve months after the baseline screening, we obtained a second blood draw from 89.6% of subjects found to have altered glycaemia levels at baseline (n=193 excluding undiagnosed diabetes), a

**Table 3** Summary of missing data for variables recorded during the first and second phase of the Mollerussa cohort

Variable of interest	Missing data, n (%)
<b>First phase (baseline screening); n=594</b>	
No clinical interview	17 (2.9)
No nutritional survey	28 (4.7)
No carotid echography	17 (2.9)
No laboratory results	0 (0.0)
No HbA1c measurement	10 (1.7)
No sample for biobank	22 (3.7)
<b>Second phase (12 months follow-up); n=193</b>	
No laboratory results	20 (10.4)

HbA1c, glycated haemoglobin.

retention rate also indicating acceptable validity of the results (table 3; figure 1).

We are currently in the phase of longitudinal follow-up of all subjects with subjects identified during the first and second phase (figure 1), and developing protocols for the analyses to explore hypotheses on different features of the epidemiology and natural history of pre-diabetes in our primary care setting. The first paper from the Mollerussa project (now in preparation) will describe results derived from the short-term follow-up of the cohort, namely the prevalence of pre-diabetes and undiagnosed diabetes, the clinical and demographic profile of patients with pre-diabetes versus those with normal glycaemic levels, a first estimation of the annual incidence of overt diabetes among subjects with pre-diabetes and the metabolic, CV and life-style disease-associated conditions.

### STRENGTHS AND LIMITATIONS

The main strength of the Mollerussa cohort is that it includes adult patients from primary care health centres prospectively collected, and the opportunity to follow participants in the long term through healthcare electronic registries, which ensures that it will be of use for multiple future research projects. The combined short-term prospective and long-term longitudinal design has both advantages and limitations.

The prospective phase (baseline screening and 12-month short-term follow-up) prevents recall bias because the risk for diabetes was assessed before the onset of the disease, and the measurement of events in a temporal sequence allows for causes to be distinguished from effects. However, we must acknowledge a potential selection bias, since we had higher rates of women and middle-aged subjects among enlisted people than among eligible but not enlisted subjects. The influence of this potential bias will be minimised through a weighting process on the prevalence estimates, although how this original unbalance may impact the results is not clear, because IFG and HbA1c detect different categories of individuals as being at risk: IFG is substantially more common among men, and its prevalence tends to plateau in middle age, while the prevalence of pre-diabetes using HbA1c increases with age (maximum peak in those aged 60–74 years) but does not differ by gender.<sup>27 28</sup> Finally, we did not perform an OGTT among enrolled individuals. Although IGT is more common than IFG in most populations, it is more sensitive but slightly less specific for identifying people who will develop diabetes.<sup>29</sup> Additionally, the OGTT has low reproducibility and it is inconvenient in terms of costs and time consumption.<sup>30</sup> Conversely, HbA1c measurement is cost-effective and improves the sensitivity of FPG in the detection of early T2DM in high-risk individuals.<sup>28 31</sup>

On the other hand, the longitudinal, long-term phase has the advantage that cohort membership is not dependent on continuing to visit the practice from which the members were recruited. While the main strength is that

this will minimise losses to follow-up, the primary limitation is that it will rely on data that may be incomplete or inconsistently measured between subjects. An additional advantage of this design is that, since the latency from pre-diabetes to overt diabetes may be longer than the initial 12 months follow-up,<sup>25</sup> the long-term follow-up will allow a more accurate estimation of the time trends (cumulative incidences) and clinical features associated with progression to diabetes.

## COLLABORATION

The Mollerussa study is open to future joint studies with external study groups. Investigators with an interest in hypotheses related to pre-diabetes are welcome to contact a member of the Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol) to submit a joint study proposal to the Scientific Committee of the institution. The group will consider these proposals if they are in accordance with the study objectives, and do not overlap with other studies already under way. If accepted, a formal written agreement will be established with the collaborative group.

### Author affiliations

<sup>1</sup>Primary Health Care Centre Igualada Nord, Consorci Sanitari de l'Anoia, Servei Català de la Salut, Barcelona, Spain

<sup>2</sup>Unitat de Suport a la Recerca, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Lleida, Spain

<sup>3</sup>Epidemiology Unit of the Cardiovascular Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain

<sup>4</sup>CIBER of Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Barcelona, Spain

<sup>5</sup>Department of Pediatrics, Obstetrics and Gynaecology, and Preventive Medicine, Autonomous University of Barcelona, Bellaterra, Spain

<sup>6</sup>Unitat de Suport a la Recerca Barcelona Ciutat, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain

<sup>7</sup>CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, Majadahonda, Madrid, Spain

<sup>8</sup>Faculty of Nursing and Physiotherapy, University of Lleida, Lleida, Spain

<sup>9</sup>Avantmèdic, & Centre Mèdic Pla d'Urgell, Mollerussa, Lleida, Spain

<sup>10</sup>Department of Endocrinology and Nutrition, Health Sciences Research Institute & University Hospital Universitari Germans Trias i Pujol, Badalona, Spain

<sup>11</sup>Primary Health Care Centre Tàrraga, Gerència d'Atenció Primària, Institut Català de la Salut, Lleida, Spain

<sup>12</sup>Primary Health Care Centre Guissona, Gerència d'Atenció Primària, Institut Català de la Salut, Lleida, Spain

<sup>13</sup>Primary Health Care Center La Mina, Gerència d'Àmbit d'Atenció Primària Barcelona Ciutat, Institut Català de la Salut, Sant Adrià de Besòs, Spain

<sup>14</sup>Primary Health Care Center Raval Sud, Gerència d'Atenció Primària, Institut Català de la Salut, Barcelona, Spain

**Correction notice** This paper has been amended since it was published Online First. Owing to a scripting error, some of the publisher names in the references were replaced with 'BMJ Publishing Group'. This only affected the full text version, not the PDF. We have since corrected these errors and the correct publishers have been inserted into the references.

**Acknowledgements** We acknowledge Mònica Gratacòs and Amanda Prowse for providing support in the manuscript preparation and editing. CIBER of Diabetes and Associated Metabolic Diseases is an initiative from Instituto de Salud Carlos III (Plan Nacional de I+D+I and Fondo Europeo de Desarrollo Regional).

**Contributors** MF, JRM and DM conceived and designed the study; MBV, JF-N, and AM participated in the study design; MBV, MF, ER, NA, MG-C, NM and AM collected the data; EC built and managed the database; JRM managed the database, contributed to data cleaning, performed the statistical analyses and contributed

to interpretation of the data; MBV, DM, JF-N and MM-C wrote the manuscript. All authors critically reviewed the manuscript and approved the final version to be published.

**Funding** This study was funded by Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol). The funding source had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; or preparation, review or approval of the manuscript.

**Competing interests** None declared.

**Patient consent** Obtained.

**Ethics approval** Ethics Committee of the Primary Health Care University Research Institute (IDIAP) Jordi Gol (P12/043).

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** This article describes the establishment of a longitudinal cohort and early findings, and full results will be submitted for peer-reviewed publication in due course. The authors are willing to share unpublished data with interested parties upon request because they contain identifying human information and are unsuitable for public deposition. Requests may be made to the corresponding author (didacmauricio@gmail.com).

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

## REFERENCES

1. ADA. American Diabetes Association. 2. classification and diagnosis of diabetes. *Diabetes Care* 2016;39:S13–S22.
2. IDF. International Diabetes Federation. Diabetes Atlas. 7th ed, 2015. <http://www.diabetesatlas.org/>. (accessed Sept 2016).
3. Mainous AG, Tanner RJ, Baker R, et al. Prevalence of prediabetes in England from 2003 to 2011: population-based, cross-sectional study. *BMJ Open* 2014;4:e005002.
4. Sorriquer F, Goday A, Bosch-Comas A, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. *Diabetologia* 2012;55:88–93.
5. Menke A, Casagrande S, Geiss L, et al. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. *JAMA* 2015;314:1021–9.
6. Ferrannini E. Definition of intervention points in prediabetes. *Lancet Diabetes Endocrinol* 2014;2:667–75.
7. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. *Diabetes Care* 2007;30:753–9.
8. Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. *Diabetes Res Clin Pract* 2007;78:305–12.
9. Tabák AG, Herder C, Rathmann W, et al. Prediabetes: a high-risk state for diabetes development. *Lancet* 2012;379:2279–90.
10. Ackermann RT, Cheng YJ, Williamson DF, et al. Identifying adults at high risk for diabetes and cardiovascular disease using hemoglobin A1c National Health and Nutrition Examination Survey 2005–2006. *Am J Prev Med* 2011;40:11–17.
11. Levitan EB, Song Y, Ford ES, et al. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. *Arch Intern Med* 2004;164:2147–55.
12. Huang Y, Cai X, Chen P, et al. Associations of prediabetes with all-cause and cardiovascular mortality: a meta-analysis. *Ann Med* 2014;46:684–92.
13. Sánchez V. *El síndrome metabólico en Lleida desde Una perspectiva clínico-epidemiológica*. Department of Medicine, University of Lleida, 2011. Doctoral thesis. <https://repositori.udl.cat/handle/10803/31999?show=full>. (accessed 08 Oct 2016).
14. ISCED. OECD/Eurostat/UNESCO Institute for Statistics. *ISCED 2011 Operational Manual: guidelines for Classifying National Education Programmes and Related Qualifications*. Paris: OECD Publishing, 2011.

15. Roman-Viñas B, Serra-Majem L, Hagströmer M, *et al.* International physical activity questionnaire: reliability and validity in a spanish population. *Eur J Sport Sci* 2010;10:297–304.
16. Chobanian AV, Bakris GL, Black HR, *et al.* The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. *JAMA* 2003;289:2560–72.
17. Vioque J. Validez de la evaluación de la ingesta dietética. In: Serra Majem L, Aranceta Bartrina J, eds. *Nutrición Y Salud Pública. Métodos, bases científicas y aplicaciones*. 2nd ed. Barcelona: Masson-Elsevier, 2006:199–220.
18. Trichopoulou A, Costacou T, Bamia C, *et al.* Adherence to a mediterranean diet and survival in a Greek population. *N Engl J Med* 2003;348:2599–608.
19. Rubinat E, Marsal JR, Vidal T, *et al.* Subclinical carotid atherosclerosis in asymptomatic subjects with type 2 diabetes mellitus. *J Cardiovasc Nurs* 2016;31:E1–E7.
20. Touboul PJ, Hennerici MG, Meairs S, *et al.* Mannheim carotid intima-media thickness consensus (2004–2006). An update on behalf of the advisory board of the 3rd and 4th watching the risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. *Cerebrovasc Dis* 2007;23:75–80.
21. Karim R, Hodis HN, Detrano R, *et al.* Relation of Framingham risk score to subclinical atherosclerosis evaluated across three arterial sites. *Am J Cardiol* 2008;102:825–30.
22. Mata-Cases M, Mauricio D, Real J, *et al.* Is diabetes mellitus correctly registered and classified in primary care? A population-based study in Catalonia, Spain. *Endocrinol Nutr* 2016;63:440–8.
23. Bolívar B, Fina Avilés F, Morros R, *et al.* [SIDIAP database: electronic clinical records in primary care as a source of information for epidemiologic research]. *Med Clin* 2012;138:617–21.
24. Generalitat de Catalunya Servei Català de la Salut. Registre del conjunt mínim bàsic de dades dels hospitals d'aguts (CMBD-HA). Especificacions de la validació de les dades, 2010. <http://www20.gencat.cat/>. (accessed 07 Oct 2016).
25. Nichols GA, Hillier TA, Brown JB. Progression from newly acquired impaired fasting glucose to type 2 diabetes. *Diabetes Care* 2007;30:228–33.
26. Song JW, Chung KC. Observational studies: cohort and case-control studies. *Plast Reconstr Surg* 2010;126:2234–42.
27. Mann DM, Carson AP, Shimbo D, *et al.* Impact of A1C screening criterion on the diagnosis of pre-diabetes among U.S. adults. *Diabetes Care* 2010;33:2190–5.
28. Droumaguet C, Balkau B, Simon D, *et al.* Use of HbA1c in predicting progression to diabetes in French men and women: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). *Diabetes Care* 2006;29:1619–25.
29. Unwin N, Shaw J, Zimmet P, *et al.* Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. *Diabet Med* 2002;19:708–23.
30. Gossain VV, Aldasouqi S. The challenge of undiagnosed pre-diabetes, diabetes and associated cardiovascular disease. *Int J Diabetes Mellit* 2010;2:43–6.
31. Perry RC, Shankar RR, Fineberg N, *et al.* HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP). *Diabetes Care* 2001;24:465–71.



## *Correction: Prevalence, clinical features and risk assessment of pre-diabetes in Spain: the prospective Mollerussa cohort study*

---

Vilanova MB, Falguera M, Marsal JR, *et al.* Prevalence, clinical features and risk assessment of pre-diabetes in Spain: the prospective Mollerussa cohort study. *BMJ Open* 2017;7:e015158. doi: 10.1136/bmjopen-2016-015158

The name of the sixth author should be 'Castelblanco' instead of 'Catelblanco'.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

*BMJ Open* 2017;7:e015158corr1. doi:10.1136/bmjopen-2016-015158corr1



CrossMark